Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

✍ Scribed by Das, Sudipto (author);Vital, Edward M. (author);Horton, Sarah (author);Bryer, Domini (author);El-Sherbiny, Yasser (author);Rawstron, Andrew C. (author);Ponchel, Frederique (author);Emery, Paul (author);Buch, Maya H. (author)

• Book ID: 126463918
• Publisher: BMJ Publishing Group
• Year: 2014
• Tongue: English
• Weight: 253 KB
• Volume: 73
• Category: Article
• ISSN: 0003-4967
• DOI: 10.1136/annrheumdis-2013-204417